Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRL-501
- Development stage
- Preclinical
- Lead developer
- BRL Medicine
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BRL-501 is an investigational anti-PSMA (prostate-specific membrane antigen) chimeric antigen receptor T-cell (CAR-T) therapy under development by BRL Medicine. It is designed to target and eliminate PSMA-positive tumor cells, which are commonly found in prostate cancer. As a cell therapy, BRL-501 genetically engineers autologous T cells to express a CAR specific for PSMA, enabling the immune system to better recognize and attack cancer cells. It is being developed primarily for the treatment of prostatic cancer and is currently in clinical development, with its highest phase of development reported as clinical.
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on BRL-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRL-501.